Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells

Shuai Han, Xin Li, Yun Xia, Zhengsen Yu, Ningning Cai, Satish R. Malwal, Xu Han, Eric Oldfield, Yonghui Zhang

Research output: Contribution to journalArticle

Abstract

Human farnesyl pyrophosphate synthase (Homo sapiens FPPS, HsFPPS) is a target for treating bone resorption diseases and some cancers. HsFPPS is potently inhibited by bisphosphonates, but due to poor cell penetration and distribution in soft tissue, there is currently interest in the development of non-bisphosphonate inhibitors as cancer therapeutics. Here, we report the discovery and development of HsFPPS inhibitors based on the phenolic diterpene carnosic acid (CA), an antimicrobial found in rosemary and sage, which showed better cellular anticancer activities than the bisphosphonate drug zoledronate in pancreatic cancer cell lines, as well as an HsFPPS-dependent mechanism of action. Hit-to-lead optimization of CA improved HsFPPS inhibition by >100-fold. A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting HsFPPS, leading to downregulation of Ras prenylation and cell apoptosis. The discovery of this series of compounds together with proof-of-mechanism in pancreatic cancer cells may pave the way for targeting HsFPPS in soft tissue cancers using natural-product-derived inhibitors.

Original languageEnglish (US)
Pages (from-to)10867-10896
Number of pages30
JournalJournal of Medicinal Chemistry
Volume62
Issue number23
DOIs
StatePublished - Dec 12 2019

Fingerprint

Drug Discovery
Biological Products
Pancreatic Neoplasms
zoledronic acid
Diphosphonates
Neoplasms
Prenylation
farnesyl pyrophosphate
Diterpenes
Bone Diseases
Bone Resorption
Down-Regulation
Apoptosis
Cell Line
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Farnesyl Pyrophosphate Synthase as a Target for Drug Development : Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells. / Han, Shuai; Li, Xin; Xia, Yun; Yu, Zhengsen; Cai, Ningning; Malwal, Satish R.; Han, Xu; Oldfield, Eric; Zhang, Yonghui.

In: Journal of Medicinal Chemistry, Vol. 62, No. 23, 12.12.2019, p. 10867-10896.

Research output: Contribution to journalArticle

Han, Shuai ; Li, Xin ; Xia, Yun ; Yu, Zhengsen ; Cai, Ningning ; Malwal, Satish R. ; Han, Xu ; Oldfield, Eric ; Zhang, Yonghui. / Farnesyl Pyrophosphate Synthase as a Target for Drug Development : Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells. In: Journal of Medicinal Chemistry. 2019 ; Vol. 62, No. 23. pp. 10867-10896.
@article{064ae588fb584b58961f207fa767c0a0,
title = "Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells",
abstract = "Human farnesyl pyrophosphate synthase (Homo sapiens FPPS, HsFPPS) is a target for treating bone resorption diseases and some cancers. HsFPPS is potently inhibited by bisphosphonates, but due to poor cell penetration and distribution in soft tissue, there is currently interest in the development of non-bisphosphonate inhibitors as cancer therapeutics. Here, we report the discovery and development of HsFPPS inhibitors based on the phenolic diterpene carnosic acid (CA), an antimicrobial found in rosemary and sage, which showed better cellular anticancer activities than the bisphosphonate drug zoledronate in pancreatic cancer cell lines, as well as an HsFPPS-dependent mechanism of action. Hit-to-lead optimization of CA improved HsFPPS inhibition by >100-fold. A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting HsFPPS, leading to downregulation of Ras prenylation and cell apoptosis. The discovery of this series of compounds together with proof-of-mechanism in pancreatic cancer cells may pave the way for targeting HsFPPS in soft tissue cancers using natural-product-derived inhibitors.",
author = "Shuai Han and Xin Li and Yun Xia and Zhengsen Yu and Ningning Cai and Malwal, {Satish R.} and Xu Han and Eric Oldfield and Yonghui Zhang",
year = "2019",
month = "12",
day = "12",
doi = "10.1021/acs.jmedchem.9b01405",
language = "English (US)",
volume = "62",
pages = "10867--10896",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "23",

}

TY - JOUR

T1 - Farnesyl Pyrophosphate Synthase as a Target for Drug Development

T2 - Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells

AU - Han, Shuai

AU - Li, Xin

AU - Xia, Yun

AU - Yu, Zhengsen

AU - Cai, Ningning

AU - Malwal, Satish R.

AU - Han, Xu

AU - Oldfield, Eric

AU - Zhang, Yonghui

PY - 2019/12/12

Y1 - 2019/12/12

N2 - Human farnesyl pyrophosphate synthase (Homo sapiens FPPS, HsFPPS) is a target for treating bone resorption diseases and some cancers. HsFPPS is potently inhibited by bisphosphonates, but due to poor cell penetration and distribution in soft tissue, there is currently interest in the development of non-bisphosphonate inhibitors as cancer therapeutics. Here, we report the discovery and development of HsFPPS inhibitors based on the phenolic diterpene carnosic acid (CA), an antimicrobial found in rosemary and sage, which showed better cellular anticancer activities than the bisphosphonate drug zoledronate in pancreatic cancer cell lines, as well as an HsFPPS-dependent mechanism of action. Hit-to-lead optimization of CA improved HsFPPS inhibition by >100-fold. A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting HsFPPS, leading to downregulation of Ras prenylation and cell apoptosis. The discovery of this series of compounds together with proof-of-mechanism in pancreatic cancer cells may pave the way for targeting HsFPPS in soft tissue cancers using natural-product-derived inhibitors.

AB - Human farnesyl pyrophosphate synthase (Homo sapiens FPPS, HsFPPS) is a target for treating bone resorption diseases and some cancers. HsFPPS is potently inhibited by bisphosphonates, but due to poor cell penetration and distribution in soft tissue, there is currently interest in the development of non-bisphosphonate inhibitors as cancer therapeutics. Here, we report the discovery and development of HsFPPS inhibitors based on the phenolic diterpene carnosic acid (CA), an antimicrobial found in rosemary and sage, which showed better cellular anticancer activities than the bisphosphonate drug zoledronate in pancreatic cancer cell lines, as well as an HsFPPS-dependent mechanism of action. Hit-to-lead optimization of CA improved HsFPPS inhibition by >100-fold. A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting HsFPPS, leading to downregulation of Ras prenylation and cell apoptosis. The discovery of this series of compounds together with proof-of-mechanism in pancreatic cancer cells may pave the way for targeting HsFPPS in soft tissue cancers using natural-product-derived inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85076242884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076242884&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.9b01405

DO - 10.1021/acs.jmedchem.9b01405

M3 - Article

C2 - 31725297

AN - SCOPUS:85076242884

VL - 62

SP - 10867

EP - 10896

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 23

ER -